Literature DB >> 15514097

Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy.

Thomas P Roddy1, Bryant C Nelson, Crystal C C Sung, Shaparak Araghi, Dennis Wilkens, X Kate Zhang, John J Thomas, Susan M Richards.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15514097     DOI： 10.1373/clinchem.2004.038323

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  11 in total

1.  Foot process effacement with normal urinalysis in classic fabry disease.

Authors:  Takahiro Kanai; Takanori Yamagata; Takane Ito; Jun Odaka; Takashi Saito; Jun Aoyagi; Masahisa Kobayashi; Toya Ohashi; Yoshihiko Ueda; Mariko Y Momoi
Journal:  JIMD Rep       Date:  2011-06-22

2.  Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I.

Authors:  Shunji Tomatsu; Adriana M Montaño; Toshihiro Oguma; Vu Chi Dung; Hirotaka Oikawa; Talita Giacomet de Carvalho; María L Gutiérrez; Seiji Yamaguchi; Yasuyuki Suzuki; Masaru Fukushi; Nobuo Sakura; Luis Barrera; Kazuhiro Kida; Mitsuru Kubota; Tadao Orii
Journal:  J Inherit Metab Dis       Date:  2010-02-17       Impact factor: 4.982

3.  Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.

Authors:  Ozlem Goker-Alpan; Michael J Gambello; Gustavo H B Maegawa; Khan J Nedd; Daniel J Gruskin; Larry Blankstein; Neal J Weinreb
Journal:  JIMD Rep       Date:  2015-08-25

4.  Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease.

Authors:  C Auray-Blais; D S Millington; S P Young; J T R Clarke; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2009-01-26       Impact factor: 4.982

5.  Lipidomics of glycosphingolipids.

Authors:  Hany Farwanah; Thomas Kolter
Journal:  Metabolites       Date:  2012-02-02

6.  Generation of GLA-Knockout Human Embryonic Stem Cell Lines to Model Autophagic Dysfunction and Exosome Secretion in Fabry Disease-Associated Hypertrophic Cardiomyopathy.

Authors:  Hui-Yung Song; Chian-Shiu Chien; Aliaksandr A Yarmishyn; Shih-Jie Chou; Yi-Ping Yang; Mong-Lien Wang; Chien-Ying Wang; Hsin-Bang Leu; Wen-Chung Yu; Yuh-Lih Chang; Shih-Hwa Chiou
Journal:  Cells       Date:  2019-04-08       Impact factor: 6.600

7.  Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.

Authors:  Dominique P Germain; Roberto Giugliani; Derralynn A Hughes; Atul Mehta; Kathy Nicholls; Laura Barisoni; Charles J Jennette; Alexander Bragat; Jeff Castelli; Sheela Sitaraman; David J Lockhart; Pol F Boudes
Journal:  Orphanet J Rare Dis       Date:  2012-11-24       Impact factor: 4.123

8.  Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.

Authors:  Frits A Wijburg; Bernard Bénichou; Daniel G Bichet; Lorne A Clarke; Gabriela Dostalova; Alejandro Fainboim; Andreas Fellgiebel; Cassiano Forcelini; Kristina An Haack; Robert J Hopkin; Michael Mauer; Behzad Najafian; C Ronald Scott; Suma P Shankar; Beth L Thurberg; Camilla Tøndel; Anna Tylki-Szymańska; Uma Ramaswami
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

9.  Enhancement of human plasma glucosylceramide assay sensitivity using delipidized plasma.

Authors:  Kefei Zheng; Allena Ji; Lee Lee Chung; Kerry Culm-Merdek; Hanlan Liu; Susan Richards; Crystal Sung
Journal:  Mol Genet Metab Rep       Date:  2016-08-07

10.  Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers.

Authors:  M Judith Peterschmitt; Nigel P S Crawford; Sebastiaan J M Gaemers; Allena J Ji; Jyoti Sharma; Theresa T Pham
Journal:  Clin Pharmacol Drug Dev       Date:  2020-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.